

515	ે જો			Attorney's Docket No. <u>032775-24</u>			
AUG 20	E CONS	IN THE UNITED ST	TATES PATENT	Γ AND TRADEMARK OFFICE			
TENT & TR		Application of	Š)			
6 14	Thompson	et al.		Group Art Unit: Unassigned			
1	Application I	No.: 10/602,024	· · · · · · · · · · · · · · · · · · ·	Examiner: Unassigned			
	Filed: June	24, 2003	· · · · · · · · · · · · · · · · · · ·	Confirmation No.: Unassigned			
		olytic Viruses as Pheno nts for Neoplasms	otyping				
£))			
	,		ATION DISCLO	SURE STATEMENT L LETTER			
	P.O. Box 14:	er for Patents 50 VA 22313-1450					
	Sir:	•					
		osed is an Information lied patent application.	Disclosure Staten	nent and accompanying form PTO-1449 for the			
	[X]	No additional fee fo	r submission of a	nn IDS is required.			
	[] The fee of \$180.00 (1806)			h in 37 C.F.R. § 1.17(p) is also enclosed.			
	[]	A statement under 3	7 C.F.R. § 1.97	C.F.R. § 1.97(e) is also enclosed.			
			37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth 7(p) are also enclosed.				
	[]	Charge \$	to Deposit A	ccount No. 02-4800 for the fee due.			
	[] A check in the amo		int of \$	is enclosed for the fee due.			
	1.17 and 1.23		by this paper, and	any appropriate fees under 37 C.F.R. §§ 1.16, d to credit any overpayment, to Deposit plicate.			
			Respectfully	submitted,			
			Burns, Doa	NE, SWECKER & MATHIS, L.L.P.			
	Date: Augu	ust 19, 2003	By: Ping F. Registra	Hwung ation No. 44,164			

P.O. Box 1404 Alexandria, Virginia 22313-1404 (650)622-2340



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Thompson et al.)
Application No.: 10/602,024) Group Art Unit: Unassigned
Filed: June 24, 2003) Examiner: Unassigned
For: Oncolytic Viruses as Phenotyping Agents for Neoplasms) Confirmation No.: Unassigned)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

United States Patents

1. U.S. Patent No. 6,136,307, Lee et al., October 24, 2000.

Foreign Patents

2. WO 94/18992, published September 1, 1994.

Articles

- 3. Bischoff JR. et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor", *Science* 274(5286):373-376 (1996).
- 4. Bos, J, "ras oncogenes in human cancer: a review", *Cancer Res.* 49:4682-4689 (1989).
- 5. Campbell, S.L. et al., "Increasing complexity of Ras signaling", *Oncogene* 17: 1395-1413 (1998).
- 6. Chandron and Nibert, "Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle", *J. of Virology* **72(1)**:467-75 (1998).
- 7. Chang et al., *J. Virol.* **69**:6605-6608 (1995).
- 8. Chang et al., *Proc. Natl. Acad. Sci.* **89**:4825-4829 (1992).
- 9. Chang et al., Virol. **194**:537-547 (1993).
- 10. Fueyo, J., et al., "A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect *in Vivo*", *Oncogene* 19(1):2-12 (2000).
- 11. Gutkind, J.S., "The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades", *J Biol Chem.* 273:1839-1842 (1998).
- 12. Kawagishi-Kobayashi, M. et al., Mol. Cell. Biol. 17:4146-4158 (1997).
- 13. Nemunaitis, J., "Oncolytic viruses", J. Invest. New Drugs 17:375-386 (1999).
- 14. Nibert, M.L., Schiff, L.A., and Fields, B.N., "Reoviruses and their replication", pages 1557-96 in *Virology* (Fields et al., 3rd Edition), Lippencott-Raven Press, 1996.
- 15. Romano et al., Mol. Cell. Bio. 18(12):7304-7316 (1998).
- 16. Sharp et al., *Virology* **250**:302-315 (1998).
- 17. Smith, R.E., et al., "Polypeptide components of virions, top component and cores of reovirus type 3", *Virology*, 39:791-800 (1969).

Information Disclosure Statement Application No. <u>10/602,024</u>

Attorney's Docket No. 032775-247

Page 3

Smith, C.A. et al., "Correlations among p53, Her-2/neu, and ras 18. overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in

infiltrating ductal carcinomas", Clin Cancer Res. 6(1):112-26 (2000).

These documents are being submitted within three months from the filing date of the

present application. Consequently, no fee is required pursuant to 37 C.F.R. §1.97(b).

By citing the above references, Applicants do not acquiesce or admit that any of these

documents is "prior art" under 35 U.S.C. Applicants specifically reserve the right, where

appropriate, to antedate any of the cited documents by an appropriate showing under 37

C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It

is respectfully requested that an Examiner initialed copy of this form be returned to the

undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _

Ping F. Hwung)

Registration No. 44,164

Attorney for Applicants

Redwood Shores, CA Office

(650)-622-2300

P.O. Box 1404

Alexandria, Virginia 22313-1404

Date: August 19, 2003

(12/97)

Substitute for forms 1449A/PTO & 1449B/PTO

AUG 2 0 2003 2 INFORMATION DISCLOSURE STATEMENT BY APPLICANTS ATTORNEY'S DKT NO.

032775-247

APPLICATION NO.

10/602,024

APPLICANT

Thompson et al.

FILING DATE

June 24, 2003

GROUP

Unassigned

		Į	J.S. PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document			Issue/Publication Date (MM-DD-YYYY)		
	6,136,307		Lee et al.		10-24-2000			
	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Document Number	Kind Code (if known)	Country		Date of Publication (MM-DD-YYYY) Yes		slation No	
	WO 94/18992		PCT	09-01-1994				
		NON PA	TENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	Bischoff JR. et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor", Science 274(5286):373-376 (1996).							
	Bos, J, "ras oncogenes in human cancer: a review", Cancer Res. 49:4682-4689 (1989).							
	Campbell, S.L. et al., "Increasing complexity of Ras signaling", Oncogene 17: 1395-1413 (1998).							
	Chandron and Nibert, "Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle", <i>J. of Virology</i> 72(1):467-75 (1998).							
	Chang et al., J. Virol. 69:6605-6608 (1995).							
	Chang et al., Proc. Natl. Acad. Sci. 89:4825-4829 (1992).							
	Chang et al., Virol. 194:537-547 (1993).							
	Fueyo, J., et al., "A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect in Vivo", Oncogene 19(1):2-12 (2000).							
	Gutkind, J.S., "The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades", <i>J Biol Chem.</i> 273:1839-1842 (1998).							
Kawagishi-Kobayashi, M. et al., Mol. Cell. Biol. 17:4146-4158 (1997).								
	Nemunaitis, J., "Oncolytic viruses", J. Invest. New Drugs 17:375-386 (1999).							
	Nibert, M.L., Schiff, L.A., and Fields, B.N., "Reoviruses and their replication", pages 1557-96 in <i>Virology</i> (Fields et al., 3rd Edition), Lippencott-Raven Press, 1996.							
	Romano et al., Mol. Cell. Bio. 18(12):7304-7316 (1998).							
	Sharp et al., Virol							
	Smith, R.E., et al., "Polypeptide components of virions, top component and cores of reovirus type 3", Virology, 39:791-800 (1969).							
	Smith, C.A. et al., "Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas", <i>Clin Cancer Res.</i> 6(1):112-26 (2000).				у			

		T	
Examiner	Date		
Signature	Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.